Figure 3 | Scientific Reports

Figure 3

From: A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector

Figure 3

Generation of BC-PIV/EGFP-EBOV-GP. (a) Mutagenesis at the RNA editing site11 results in the production of only the full-length form of the GP protein, composed of 676 amino acids. (b) A schematic illustration of BC-PIV/EGFP-EBOV-GP. Double mutations (F88A and F535A) abolish the GP-mediated viral growth. (c) A schematic illustration of the vector with the full-length EBOV-GP. (d) A schematic illustration of the vector with a hybrid protein composed of the extracellular (EC) domain of EBOV-GP with transmembrane (TM) and cytoplasmic tail (CT) regions of hPIV2 F.

Back to article page